NeuroTech startup Connectome has secured approximately $2 million in pre-seed funding to advance its mission of personalizing cognitive health monitoring. The Zurich and London-based company aims to transform brain interpretation by making it measurable and accessible. This investment will fuel the development of its platform, which provides a clearer view of an individual's cognitive well-being.
Addressing a Gap in Cognitive Health
Connectome was founded to address the significant lag in brain health assessment compared to advancements in physical health measurement. CEO Lucas Scherdel highlights a quiet deterioration in cognitive health, evidenced by rising burnout and memory issues. The company argues that modern environments place unprecedented demands on the brain without adequate tools for early detection or protection.
The startup's core mission is to close this gap by shifting from isolated snapshots to longitudinal monitoring of brain function. This approach allows for the creation of personalized models that can inform future clinical care and track disease progression. Connectome believes understanding the brain is essential for both individual well-being and broader societal resilience.
A Novel Approach to Brain Measurement
The company’s first product personalizes brain measurement by monitoring activity multiple times to establish an individual baseline. This method contrasts sharply with traditional static assessments that fail to capture dynamic changes in cognitive function. By integrating brain data with lifestyle factors like sleep and activity, the platform connects neural shifts to real-world influences.
This innovative technology is built upon foundational research conducted with Imperial College London. The pivotal LUCID study demonstrated that everyday behaviors leave a distinct and measurable signature in a person's brain activity. These findings provide a scientific basis for applying brain activity measurement in real-world, daily situations to enhance cognitive understanding.
The Science of Personalized Baselines
Co-founder and CSO Dr. Rufus Mitchell-Heggs explains that healthy brain blood flow operates within a specific zone of activity. Neurological disorders can cause brain activity to drift away from this normal zone over time. By repeatedly measuring the brain, Connectome can map these trajectories to better understand cognitive impairment risks.
This approach holds significant potential for transforming the management of conditions such as ADHD and dementia. It enables the earlier detection of subtle cognitive changes long before they reach traditional clinical thresholds. The platform is designed to support research and decision-making, providing objective and actionable insights into improving cognition.
Leadership and Strategic Investment
The company was founded in 2024 by seasoned neuroscientists Lucas Scherdel and Dr. Rufus Mitchell-Heggs, who bring extensive experience from global R&D and computational neuroscience. The $2 million funding round was led by Redstone, with participation from Concept Ventures and Octopus. The investment also includes over $115,000 in non-dilutive public innovation funding, reflecting strong confidence in the venture.
With this new capital, Connectome plans to launch its product with a select group of initial partners. The funding will also be used to advance research and development efforts into new use cases. The company aims to expand its technology's application beyond lifestyle and wearable devices into broader health contexts.
Connectome's successful pre-seed funding round marks a significant step forward in the field of NeuroTech. By pioneering a personalized and longitudinal approach to brain health, the company is poised to redefine our understanding of cognitive well-being. This innovation promises to make brain health assessment more objective, proactive, and integral to overall human health.